美敦力高层大换血！两大核心业务同步换帅

Core Insights - Medtronic is undergoing significant organizational changes, focusing on its core business areas of Cardiovascular and Cranial & Spinal Therapies (CST) to enhance growth and execution capabilities [1][2][9] Personnel Adjustments - Sean Salmon, a long-time executive with over 20 years at Medtronic, will officially leave in September 2025, with Skip Kiil taking over his role. Kiil has a strong background in AI and robotics integration [2][4] - Michael Carter has been promoted to lead the CST division, bringing extensive experience in neuroscience and digital strategies, which aligns with the company's current focus [6][8] Business Performance - Medtronic reported a revenue of $33.5 billion for the fiscal year 2025, marking a 3.6% year-over-year increase, with a net profit of $4.66 billion. Both core business segments showed growth [8][11] - The Cardiovascular segment generated $12.48 billion in revenue, up 6.3%, driven by products like PulseSelect and Micra, while the CST segment achieved $9.85 billion, growing 5% [11] Strategic Focus - The company is initiating a spin-off of its diabetes segment, expected to be completed within 18 months, while concentrating on its main areas of Cardiovascular and Neuroscience [9] - The leadership changes and business restructuring signal Medtronic's intent to enhance internal execution and adapt to market and technological challenges [9][11]